Phase I Study of the Humanized Mik-Beta-1 Monoclonal Antibody Directed Toward IL-2/IL-15R Beta (CD122) That Blocks IL-15 Action In Patients With Refractory Celiac Disease
Trial status: Open for Enrollment
Why is this study being done?
- Celiac disease is a complex inflammatory disorder with an autoimmune component characterized by a dramatic expansion of intraepithelial cytotoxic T lymphocytes that usually regress on a gluten-free diet.
- It is estimated that approximately 10% of patients become refractory on a gluten-free diet.
- A subgroup of refractory celiac disease is characterized by expansion of a highly oligoclonal intraepithelial T-lymphocyte population that exhibits a high risk of developing enteropathy associated T-cell lymphoma (EATL).
- There is presently no effective therapy for refractory celiac disease.
- A number of studies indicate that intestinal epithelial derived IL-15 plays a critical role in the disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis that characterizes refractory celiac disease.
- A pivotal role for IL-15 in refractory celiac disease and EATL is further supported by the finding that in two murine models of celiac disease the pathognomonic features were reversed completely by administration of an antibody to CD122 (IL-2/IL-15R beta) that blocks IL-15 transpresentation and action.
- A Phase I clinical trial in patients with T-cell LGL and hematocytopenia using the monoclonal antibody, Hu-Mik-Beta-1 that blocks IL-15 action produced under cGMP conditions by the BDP NCI has been completed in the Metabolism Branch, NCI at the Clinical Center NIH.
- Phase I trial to define the safety of Hu-Mik-Beta-1 infusions to 3 groups of 3 patients each with refractory celiac disease at escalating 0.5, 1.0, and 1.5 mg/kg doses.
- To define the clinical efficacy of Hu-Mik-Beta-1 infusions in 9 patients with refractory celiac disease and to correlate these findings with celiac disease specific tests.
- Definition of the receptor saturation capacity on CD122 (IL-2/IL-15R beta) of intravenously administered Hu-Mik-Beta-1 administered at 0.5, 1.0 and 1.5 mg/kg body weight to 3 groups of patients on three occasions separated by 3 weeks in patients with refractory celiac disease.
- Determine the immunogenicity of intravenously administered Hu-Mik-Beta-1.
- Determine the effects of Hu-Mik-Beta-1 on the phenotype and the state of activation of the elements of the cellular immune system in the circulation and in intestinal biopsies with special focus on the cells implicated in the pathogenesis of celiac disease.
- Patients with refractory celiac disease (RCD) defined by the following internationally accepted criteria: persistent or recurrent symptoms (diarrhea, weight loss, and abdominal pain) associated with intestinal damage characterized by partial to total villous atrophy with intraepithelial lymphocytes (defined by > 25 intraepithelial lymphocytes per 100 epithelial cells) despite strict adherence to a gluten-free diet for 6-12 months.
- Lack of antibodies to Hu-Mik-Beta-1.
- Patients are not to have circulating antibodies to tissue transglutaminase that are greater than 10 assay units using recombinant human transglutaminase antibodies.
- Patients will be enrolled and treated at the Mayo Clinic with the University of Chicago and the Clinical Center at the NIH involved as laboratory sites. This is a nonrandomized openlabel phase I trial.
- In this phase I trial initial patients are enrolled to receive 0.5 mg/kg of Hu-Mik-Beta-1 (3 patients). Patients receive Hu-Mik-Beta-1 every 3 weeks for a total of 3 doses (given on day 1, week 3 and week 6). At specific points in time the patients are monitored (see below). If 1 or more of the 3 patients receiving 0.5 mg/kg of Hu-Mik-Beta-1 experience a NCI CTCAE version 4.0 grade 3 or greater toxicity with the exception of fatigue of > 4days duration possibly, probably or definitely related to the infusion of Hu-Mik-Beta-1, subject enrollment and dosing is stopped.
- At the completion of Week 9, the safety data are reviewed by the Sponsor and DSMB. If the safety data in the 0.5 mg/kg cohort are acceptable, the Sponsor may then enroll additional patients in doses greater than 0.5 mg/kg, evaluated in a similar manner as the 0.5 mg/kg (e.g., 3 more patients to receive 1 mg/kg Hu-Mik-Beta-1 every 3 weeks for a total of 3 doses.
- The steps described above are repeated and if safety data in the 1 mg/kg cohort are acceptable, the Sponsor may then enroll 3 more patients to receive 1.5 mg/kg Hu-Mik-Beta-1 every 3 weeks for a total of 3 doses, etc.).
- The steps described above are repeated and if safety data in the 1.5 mg/kg cohort are acceptable, the Sponsor may enroll an additional 3 patients to receive 1.5 mg/kg Hu-Mik- Beta-1 every 3 weeks for a total of 3 doses.
- At specific points in time the following cardiac tests/studies are obtained, the results reviewed prior to subsequent doses (at week 3 and week 6):
i. EKG at screening (Week -4 to 0), Day 1, Week 3, Week 6 and Week 7.
ii. CK-MB and troponin I at screening (Week -4 to 0), Day 1, Day 7, Week 3, Week 6, and Week 7.
In addition, an echocardiogram at screening (Week -4 to 0) and Week 7.
- FACS of peripheral blood mononuclear cells and peroral intestinal biopsies for expression of NKG2D, CD94, NKG2C, NKG2A, NKb44, NKb30, CD158 and granzyme.
- Immune profiling on intestinal biopsies performed on the first infusion and one week + or -3 days following the third infusion to analyze for CD8 T-cells, TCR gamma rearrangements by multiplex PCR and fluorescence analysis of CD8 and CD3 expression, high-resolution PCR expression for immunoglobulin gene rearrangement and for IEL, ERK and JNK phosphorylation reflecting abnormal IEL activation.
- Furthermore, IL-15, IL-15R alpha and interferon alpha expression will be assayed in the cells of the intestinal biopsy and in the serum.
- FACS of PBMCs with Hu-Mik-Beta-1 and Hu-Mik-Beta-3 to define saturation of CD122 (IL2/IL-15R beta).
- Complete clinical response and by clinical biochemical results at the 20-week time point.
- Secondary partial response, duration of response, toxicities, immunogenicity of Hu-Mik-Beta- 1.
Who is eligible to participate?
- INCLUSION CRITERIA
22.214.171.124 Patients must be greater than or equal to 18-years-old.
126.96.36.199 All patients must have a pathologically confirmed diagnosis of refractory celiac disease(RCD) defined by internationally accepted criteria of persistent and recurrent symptoms(diarrhea, weight loss, and abdominal pain) associated with intestinal damage, characterized by partial to total villous atrophy with intraepithelial lymphocytes defined by > 25 intraepithelial lymphocytes per 100 epithelial cells.
188.8.131.52 Persistence of the above signs and symptoms despite strict adherence to a gluten-free diet for 6-12 months
184.108.40.206 Patients are to have had circulating antibodies to transglutaminase-1 or similar celiac specific serology
220.127.116.11 Patients must have a life expectancy of > 3 months
18.104.22.168 Patients must have a creatinine of less than 2.0 mg/dL or if the patient has an elevated creatinine measured creatinine clearance (Ccr) must be > 60 mL/min/1.73m(2)
22.214.171.124 Patients must have a serum alkaline phosphatase, ALT (SGPT) and AST (SGOT) less than 3x the upper limits of normal (ULN)
126.96.36.199 Patients must have a total bilirubin of less than 2.5 x ULN
188.8.131.52 Women of childbearing potential must have a negative beta HCG pregnancy test at initial screening and within 3 days prior to registration
184.108.40.206 Patients receiving a stable dose (> 4 weeks) of corticosteroid therapy equal to 20 mg of prednisone per day or less are eligible
220.127.116.11 Patients with a history of curatively treated basal cell carcinoma or intraepithelial neoplasia of the uterine surface will be allowed on the study
18.104.22.168 Patients must be able to understand and sign an informed consent
22.214.171.124 Patients enrolled in another therapeutic study
126.96.36.199 Patients with a history of venous thrombosis
188.8.131.52 Patients with antibodies to Hu-Mik-Beta-1
184.108.40.206 A contraindication to monoclonal antibody therapy including adverse events related to prior monoclonal antibody therapy. Patients who have received prior antibody therapy will have permanent medical records reviewed by the study investigator.
220.127.116.11 Any uncontrolled or chronic bacterial, mycobacterial or other viral (e.g., herpes virus), fungal, parasitic or protozoal infection
18.104.22.168 History of malignancy (active or within the previous 5 years)
22.214.171.124 Patients with HIV infection (antibody positive) with positive confirmatory molecular tests
126.96.36.199 Patients who have chronic hepatitis B or chronic hepatitis C
188.8.131.52 Pregnant or breastfeeding women. Women who not using an acceptable method of contraception. Acceptability of various methods of contraception will be determined by the investigator. Postmenopausal or surgically sterile women who have documentation of postmenopausal status or surgical sterility availability prior to enrollment.
184.108.40.206 Patients with significant co-morbidities including uncontrolled hypertension (diastolic B/P > 115 mm/Hg), unstable angina, congestive heart failure (> N.Y.H.A. Class II), poorly controlled diabetes, severe chronic pulmonary disease, coronary angioplasty or myocardial infarction within the last 6 months or uncontrolled atrial or ventricular cardiac arrhythmias.
220.127.116.11 Abnormal screening/baseline tests exceeding the limits outlined below:
- Total white blood cell count (WBC) < 300/mm(3)
- Platelet count < 85,000/mm(3)
- INR greater than or equal to 1.5
- Serum creatinine level > 1.5 mg/dL
- Serum alanine transaminase, aspartate transaminase or creatinine kinase > 2 x the upper limits of normal
18.104.22.168 Patients with a history of a psychiatric disorder that may interfere with the understanding and compliance with this protocol, and the required follow-up
22.214.171.124 Exclusion at the discretion of the PI or delegate if participation in the study is deemed too risky (e.g., clinically significant pleural or pericardial effusion or ascites)
126.96.36.199 Inability to give informed consent